soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM โ (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine ๐งช T2DM + ASCVD/CKD ๐ Oral semaglutide 14 mg vs placebo ๐ Oral Semaglutide and Cardiovascular Outcomes
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 7 - Aug 12


























